Lacidipine is a highly lipophilic dihydropyridine L-type calcium-channel blocker developed for treatment of essential hypertension. Its lipophilicity gives it a slow onset and sustained vascular effect, which supports once-daily dosing and prolonged blood-pressure control. Clinical reviews describe it as effective and generally well tolerated for long-term management of hypertension.

Technical Data

Name: Lacidipine

CAS: 103890-78-4

Purity: ≥98% 

Appearance: white to off-white powder

Assay method: HPLC

Packaging: 1 kg / 5 kg / 25 kg fiber drums

Documents: COA, MSDS, GMP support, stability data available

Lacidipine selectively inhibits L-type (voltage-gated) calcium channels in vascular smooth muscle → reduces Ca²⁺ influx → arterial vasodilation → decreased peripheral resistance and lower blood pressure. Because it preferentially relaxes vascular smooth muscle over myocardium, it typically produces less negative inotropy than non-dihydropyridine agents. Its high lipophilicity contributes to a longer duration of action.

Treatment of essential hypertension

First-line or add-on therapy in patients who require smooth, sustained vasodilation

Patients sensitive to rapid-acting CCBs who prefer a slower onset and stable hemodynamic response

Combination therapy with ACE inhibitors, ARBs, beta-blockers, or diuretics

Lacidipine Dose Guide (2 mg / 4 mg / 6 mg / 10 mg / 20 mg)

Typical starting dose: 2 mg once daily

Common therapeutic dose: 4 mg once daily

Lacidipine 6 mg: used in patients with partial BP response to 4 mg

Lacidipine 10 mg: upper mid-range dose used in resistant hypertension or combination therapy

Lacidipine 20 mg: seen in some markets as a maximal titration level (not available everywhere; depends on local regulatory labeling)

Always follow local prescribing guidelines, as dosage strength availability varies by region.

common adverse effects

Common adverse effects are similar to other dihydropyridine CCBs and reflect vasodilation:

• Headache, dizziness, flushing, peripheral edema (ankle swelling) - typical for dihydropyridines.
• Reflex tachycardia is possible but lacidipine's vascular selectivity and slow onset may blunt large reflex responses vs faster CCBs.
• Other: rarely hypotension, palpitations, GI complaints.

Overall lacidipine is described as generally well tolerated in clinical studies. Monitor renal/hepatic function and drug interactions (CYP metabolism possible). 

Patients focus on side effects & tolerability: common patient threads discuss peripheral edema, dizziness, and finding the CCB with "least side effects." Some users report switching drugs when edema or other AEs occur.

Clinical threads: paramedic/ED/professional forums discuss antihypertensive protocols and acute vs chronic use; lacidipine is less commonly mentioned than mainstream agents (amlodipine, nifedipine), but is discussed as an option in literature reviews.

Conclusion: highlight tolerability data, 24-hour BP control, once-daily dosing, and published clinical reviews - these are the points clinicians and patients care about. Also be transparent about common AEs (edema, dizziness) - forum credibility is increased when you address patient concerns directly.

Hottags：

Lacidipine API, Lacidipine raw material, Lacidipine supplier, Lacidipine manufacturer, Buy Lacidipine powder, Lacidipine CAS 103890-78-4, Lacidipine GMP supplier, High purity Lacidipine, Pharmaceutical grade Lacidipine, Lacidipine wholesale, Lacidipine factory price, Lacidipine COA available, Lacidipine DMF support
Lacidipine bulk supply, Lacidipine in stock, Lacidipine exporter China, Lacidipine contract manufacturing, Lacidipine for formulation, Lacidipine API distributor
 

Hot Tags: lacidipine cas 103890-78-4, China lacidipine cas 103890-78-4 manufacturers, suppliers, factory, cu peptide, Melanotan Ii Skincare, s acetyl l glutathion 200 mg, GHK Cu, coq10 100mg, glutacid l glutathione